North Star Asset Management Inc. Has $12.17 Million Stock Holdings in Eli Lilly and Company $LLY

North Star Asset Management Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,606 shares of the company’s stock after selling 476 shares during the period. North Star Asset Management Inc.’s holdings in Eli Lilly and Company were worth $12,166,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. FourThought Financial Partners LLC increased its position in Eli Lilly and Company by 36.1% in the second quarter. FourThought Financial Partners LLC now owns 3,160 shares of the company’s stock worth $2,463,000 after buying an additional 839 shares during the last quarter. Associated Banc Corp grew its stake in Eli Lilly and Company by 1.6% during the second quarter. Associated Banc Corp now owns 55,366 shares of the company’s stock valued at $43,159,000 after acquiring an additional 869 shares in the last quarter. Elo Mutual Pension Insurance Co increased its holdings in shares of Eli Lilly and Company by 7.6% in the second quarter. Elo Mutual Pension Insurance Co now owns 78,035 shares of the company’s stock worth $60,831,000 after purchasing an additional 5,509 shares during the period. Resolute Wealth Strategies LLC raised its holdings in shares of Eli Lilly and Company by 1.4% in the 2nd quarter. Resolute Wealth Strategies LLC now owns 1,365 shares of the company’s stock valued at $1,064,000 after acquiring an additional 19 shares in the last quarter. Finally, Southeast Asset Advisors LLC lifted its position in Eli Lilly and Company by 21.4% during the second quarter. Southeast Asset Advisors LLC now owns 647 shares of the company’s stock valued at $504,000 after purchasing an additional 114 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on LLY shares. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Morgan Stanley raised their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday. CICC Research upped their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Finally, The Goldman Sachs Group raised their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,067.68 on Tuesday. The business has a 50 day simple moving average of $862.28 and a two-hundred day simple moving average of $790.04. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,075.72. The stock has a market capitalization of $1.01 trillion, a PE ratio of 69.78, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.